AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Singh, K. V.
Right arrow Articles by Murray, B. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Singh, K. V.
Right arrow Articles by Murray, B. E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2000, p. 3434-3437, Vol. 44, No. 12
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Efficacy of Telithromycin (HMR 3647) against Enterococci in a Mouse Peritonitis Model

Kavindra V. Singh,1,2,* Karen K. Zscheck,1,2 and Barbara E. Murray1,2,3

Center for the Study of Emerging and Re-Emerging Pathogens,1 Division of Infectious Diseases, Department of Internal Medicine,2 and Department of Microbiology and Molecular Genetics,3 The University of Texas Medical School, Houston, Texas 77030

Received 29 March 2000/Returned for modification 8 May 2000/Accepted 31 August 2000

We used a mouse peritonitis model to evaluate the in vivo efficacy of telithromycin (HMR 3647) (TEL) and erythromycin (ERY) against four strains of Enterococcus faecalis and three strains of Enterococcus faecium with differing susceptibilities to TEL. TEL was highly active in vivo against Ery-susceptible (Erys) and -intermediate (Eryi) strains (MIC of TEL = 0.015 to 0.062 µg/ml) and showed less efficacy against Ery-resistant (Eryr) isolates (MIC of TEL = 4 to 16 µg/ml), although this was overcome in part by a second subcutaneous dose. Quinupristin-dalfopristin was also noted to have less efficacy against Eryr versus Erys or Eryi E. faecium strains, but this difference was reduced by intravenous administration. In conclusion, TEL was more potent in vivo against enterococci than was ERY; its activity was lowered by the presence of erm(B)-mediated Eryr.

* Corresponding author. Mailing address: Center for the Study of Emerging and Re-Emerging Pathogens, University of Texas Medical School---Houston, 6431 Fannin, 1.728 JFB, Houston, TX 77030. Phone: (713) 500-6767. Fax: (713) 500-5495. E-mail: Kavindra.Singh{at}uth.tmc.edu.

Antimicrobial Agents and Chemotherapy, December 2000, p. 3434-3437, Vol. 44, No. 12
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2000 by the American Society for Microbiology. All rights reserved.